The Effectiveness of Intravenous Golimumab Administered Directly After Infliximab in Rheumatoid Arthritis Patients.

MLA

Bray, Vance J., et al. “The Effectiveness of Intravenous Golimumab Administered Directly After Infliximab in Rheumatoid Arthritis Patients.” Drugs in R&D, vol. 18, no. 3, Sept. 2018, pp. 211–19. EBSCOhost, https://doi.org/10.1007/s40268-018-0240-1.

APA

Bray, V. J., Broadwell, A., Baraf, H. S. B., Black, S., Brady, B. L., Tkacz, J., Yarngo, L., & DeHoratius, R. J. (2018). The Effectiveness of Intravenous Golimumab Administered Directly After Infliximab in Rheumatoid Arthritis Patients. Drugs in R&D, 18(3), 211–219. https://doi.org/10.1007/s40268-018-0240-1

Chicago

Bray, Vance J, Aaron Broadwell, Herbert S B Baraf, Shawn Black, Brenna L Brady, Joseph Tkacz, Lorraine Yarngo, and Raphael J DeHoratius. 2018. “The Effectiveness of Intravenous Golimumab Administered Directly After Infliximab in Rheumatoid Arthritis Patients.” Drugs in R&D 18 (3): 211–19. doi:10.1007/s40268-018-0240-1.